Integrated BioPharma starts PhytoSel phase 1 trial

By Elaine Rigoli

Tampa, Fla., July 10 - INB:Biotechnologies, Inc., a wholly owned subsidiary of Integrated BioPharma Inc., has started dosing of PhytoSel in a phase 1 clinical trial.

The study, conducted at City of Hope in Duarte, Calif., will examine whether high doses of Phytosel, INB's plant-derived oral formulation of selenium, can reduce the negative side effects of two chemotherapeutic drugs.

The trial is expected to take about one year to complete, according to a news release.

PhytoSel has been marketed within the nutraceutical industry for several years as a natural selenium supplement. The micronutrient consists of organic selenium compounds that are produced using INB's patented hyperaccumulation process.

Integrated BioPharma is a pharmaceutical company located in Hillside, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.